Ramucirumab and GSK1838705A Enhance the Inhibitory Effects of Low Concentration Sorafenib and Regorafenib Combination on HCC Cell Growth and Motility
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Ramucirumab and GSK1838705A Enhance the Inhibitory Effects of Low Concentration Sorafenib and Regorafenib Combination on HCC Cell Growth and Motility
Authors
Keywords
-
Journal
Cancers
Volume 11, Issue 6, Pages 787
Publisher
MDPI AG
Online
2019-06-07
DOI
10.3390/cancers11060787
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Chlorogenic Acid Improves the Regorafenib Effects in Human Hepatocellular Carcinoma Cells
- (2018) Maria Refolo et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial
- (2018) Masatoshi Kudo et al. LANCET
- Strong enhancement by IGF1-R antagonists of hepatocellular carcinoma cell migration inhibition by Sorafenib and/or vitamin K1
- (2018) Rosalba D’Alessandro et al. CELLULAR ONCOLOGY
- Molecular therapies and precision medicine for hepatocellular carcinoma
- (2018) Josep M. Llovet et al. Nature Reviews Clinical Oncology
- Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2017) Jordi Bruix et al. LANCET
- IGF-1R tyrosine kinase inhibitors and Vitamin K1 enhance the antitumor effects of Regorafenib in HCC cell lines
- (2017) Maria Grazia Refolo et al. Oncotarget
- A phase I study of AVE1642, a human monoclonal antibody–blocking insulin-like growth factor-1 receptor (IGF-1R), given as a single agent and in combination with sorafenib as first-line therapy in patients with advanced hepatocellular carcinoma (HCC).
- (2017) S. J. Faivre et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II study of cixutumumab (IMC-A12, NSC742460; C) in hepatocellular carcinoma (HCC).
- (2017) G. K. Abou-Alfa et al. JOURNAL OF CLINICAL ONCOLOGY
- Multikinase inhibitor regorafenib inhibits the growth and metastasis of colon cancer with abundant stroma
- (2016) Hidehiko Takigawa et al. CANCER SCIENCE
- Low Alpha-Fetoprotein Levels Are Associated with Improved Survival in Hepatocellular Carcinoma Patients with Portal Vein Thrombosis
- (2015) Brian I. Carr et al. DIGESTIVE DISEASES AND SCIENCES
- Tumour initiating cells and IGF/FGF signalling contribute to sorafenib resistance in hepatocellular carcinoma
- (2015) Victoria Tovar et al. GUT
- Telomerase Inhibition Decreases Alpha-Fetoprotein Expression and Secretion by Hepatocellular Carcinoma Cell Lines: In Vitro and In Vivo Study
- (2015) Roula Tahtouh et al. PLoS One
- Platelet extracts induce growth, migration and invasion in human hepatocellular carcinoma in vitro
- (2014) Brian I Carr et al. BMC CANCER
- Autocrine vascular endothelial growth factor signaling promotes cell proliferation and modulates sorafenib treatment efficacy in hepatocellular carcinoma
- (2014) Sui Peng et al. HEPATOLOGY
- Vertical blockade of the IGFR- PI3K/Akt/mTOR pathway for the treatment of hepatocellular carcinoma: the role of survivin
- (2014) Da-Liang Ou et al. Molecular Cancer
- IGF-1R as an anti-cancer target--trials and tribulations
- (2013) Helen X. Chen et al. Chinese Journal of Cancer
- Plasma Biomarkers as Predictors of Outcome in Patients with Advanced Hepatocellular Carcinoma
- (2012) J. M. Llovet et al. CLINICAL CANCER RESEARCH
- Effects of low concentrations of Regorafenib and Sorafenib on human HCC cell AFP, migration, invasion, and growth in vitro
- (2012) Brian I. Carr et al. JOURNAL OF CELLULAR PHYSIOLOGY
- Evaluation of regorafenib in colorectal cancer and GIST
- (2012) Tom Waddell et al. LANCET
- Regorafenib (BAY 73-4506): A new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity
- (2010) Scott M. Wilhelm et al. INTERNATIONAL JOURNAL OF CANCER
- Des-γ-carboxyprothrombin, α-fetoprotein and AFP-L3 in patients with chronic hepatitis, cirrhosis and hepatocellular carcinoma
- (2008) Francisco A Durazo et al. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
- Sorafenib in Advanced Hepatocellular Carcinoma
- (2008) Josep M. Llovet et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tumor Angiogenesis
- (2008) Robert S. Kerbel NEW ENGLAND JOURNAL OF MEDICINE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now